Exemestane

Introduction Overview

Generic Name

exemestane

Brand Name

Aromasin

Dosage Form

oral tablet

Drug Class

Aromatase inhibitors; Hormones / antineoplastics

Pharmacokinetics

Absorption: Exemestane is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 2 hours. The absorption is enhanced when taken after a meal, which increases its bioavailability. This feature supports the clinical recommendation to administer exemestane after food to optimize systemic exposure. The absolute bioavailability of exemestane is moderate due to first-pass hepatic metabolism. Factors such as gastrointestinal pH, motility, and presence of food may influence absorption, but food mainly increases bioavailability without affecting tolerability or efficacy.

Distribution: Exemestane exhibits extensive distribution in the body tissues. It is highly lipophilic and binds extensively to plasma proteins, primarily albumin, with a binding rate exceeding 90%. Volume of distribution is relatively large, reflecting widespread tissue penetration, including breast tissues where the drug exerts its antineoplastic effects. In postmenopausal women, tissue distribution supports effective aromatase inhibition within breast tumor microenvironments. Exemestane does not significantly cross the blood-brain barrier, limiting central nervous system penetration.

Metabolism: The metabolism of exemestane is primarily hepatic, mediated by cytochrome P450 enzymes, especially CYP3A4, along with reduction and conjugation pathways. It undergoes irreversible suicide inhibition of aromatase by covalent binding to the enzyme’s active site. This unique mechanism underlies its clinical efficacy and distinguishes it from non-steroidal aromatase inhibitors. Exemestane's major metabolites have minimal aromatase inhibitory activity and are excreted mainly in urine. Enzyme-inducing drugs like rifampicin can increase exemestane metabolism, reducing plasma concentrations and possibly necessitating dose adjustments.

Elimination: The elimination half-life of exemestane averages approximately 24 hours, supporting once-daily dosing. Excretion occurs predominantly via renal and biliary routes as inactive metabolites. Less than 10% of unchanged drug is recovered in urine. Renal impairment does not significantly affect exemestane clearance, but hepatic insufficiency may alter metabolism and systemic exposure. Steady-state plasma concentrations are typically achieved within 7 days of consistent dosing. Clinical monitoring is important in patients with hepatic dysfunction to avoid accumulation and toxicity.

Dosage Forms

Available Dosage Forms:
Exemestane is available exclusively as oral tablets intended for daily administration. The formulations include:
- Oral tablet 25 mg

Dosages for Adults and Adolescents:
The recommended dose for postmenopausal women with early or advanced hormone-sensitive breast cancer is 25 mg orally once daily after a meal. This dosing regimen is designed to maintain effective continuous aromatase inhibition.

Specific Patient Populations:
- Postmenopausal women constitute the primary treated population; exemestane is contraindicated in premenopausal women and males.
- Dose adjustments are not generally required for mild to moderate renal impairment.
- Caution and clinical monitoring are advised in patients with hepatic impairment; dosing modifications may be necessary due to altered metabolism.
- Exemestane should not be used during pregnancy or breastfeeding.

Clinical Guidelines:
Treatment commonly follows 2 to 3 years of tamoxifen therapy in early breast cancer patients to complete a total of 5 years of adjuvant hormone therapy. In advanced breast cancer, exemestane is used after tamoxifen failure or resistance. Adherence to once-daily dosing and timing with food enhances efficacy and tolerability.

Mechanism Of Action

Exemestane is a steroidal irreversible aromatase inhibitor that targets the aromatase enzyme (CYP19A1) responsible for converting androgens into estrogens in peripheral tissues, primarily in adipose tissue and breast cancer cells in postmenopausal women. By covalently binding to the active site of aromatase, exemestane permanently inactivates the enzyme through a process known as suicidal inhibition. This irreversible blockade leads to a drastic reduction in systemic estrogen levels.

At the cellular level, lower estrogen availability results in decreased activation of estrogen receptors, which play a pivotal role in the growth and proliferation of hormone-dependent breast cancer cells. Without sufficient estrogenic stimulation, these cancer cells undergo growth arrest and apoptosis. The downstream effects include diminished expression of estrogen-regulated genes involved in cell cycle progression and survival.

Biochemically, exemestane is structurally related to androstenedione, the natural substrate of aromatase, allowing it to effectively compete with endogenous androgens for enzymatic activity. This structural mimicry facilitates selective inhibition without significant off-target interactions with other steroidogenic enzymes, reducing adverse hormonal effects.

Clinical studies have demonstrated that exemestane significantly reduces circulating estradiol and estrone concentrations by over 85%, contributing to its efficacy in managing hormone receptor-positive breast cancer. Compared to non-steroidal aromatase inhibitors like anastrozole and letrozole, exemestane’s irreversible inhibition provides a sustained suppression of estrogen synthesis, which may translate into clinical benefits in some patient populations. Ongoing research continues to explore the comparative molecular effects and potential benefits of this distinct mechanism.

Pharmacological Actions

Irreversible inhibition of aromatase enzyme, leading to suppression of estrogen synthesis.
Reduction of systemic estrogen levels in postmenopausal women, diminishing estrogen-dependent tumor growth.
Selective action on peripheral aromatase without significant effects on ovarian estrogen production.
Induction of apoptosis and growth arrest in hormone-sensitive breast cancer cells.
Minimal interference with other steroidogenic enzymes, limiting off-target hormonal effects.
Modulation of estrogen receptor signaling pathways by reducing ligand availability.
Improvement in progression-free and overall survival in hormone-receptor positive breast cancer patients when used as adjuvant or second-line therapy.
Absence of estrogen agonist effects, which differentiates it from selective estrogen receptor modulators.
Potential impacts on bone metabolism due to estrogen depletion, necessitating monitoring.
Contributes to a reduction in tumor size and metastatic spread by depriving cancer cells of growth signals.

Therapeutic Or Clinical Uses

Adjuvant treatment of early hormone receptor-positive breast cancer in postmenopausal women after 2-3 years of tamoxifen to complete 5 years of hormonal therapy.
Treatment of advanced or metastatic hormone-sensitive breast cancer in postmenopausal women after failure or intolerance to tamoxifen.
Reduction of estrogen levels to inhibit growth of estrogen-dependent breast tumors in postmenopausal patients.
Alternative to tamoxifen or non-steroidal aromatase inhibitors in adjuvant hormonal therapy regimens.
Management of hormone-sensitive breast cancer not responsive to tamoxifen.
Use in breast cancer patients with contraindications to other hormonal therapies due to its steroidal mechanism.
Part of combined regimens in clinical trials investigating synergistic effects with targeted therapies.
Potential off-label use in selective cases of estrogen-driven gynecological cancers under investigative protocols.
Employed as a strategy to delay recurrence of hormone receptor-positive breast cancer post-primary therapy.
Utilized in patients intolerant to other aromatase inhibitors due to differing side effect profiles.

Side Or Adverse Effects

Hot flashes or flushing episodes are among the most common adverse effects.
Fatigue or feelings of tiredness affecting patient quality of life.
Nausea, which may be mild to moderate and usually transient.
Musculoskeletal complaints including joint pain (arthralgia) and stiffness.
Headache of varying intensity reported by some patients.
Insomnia or difficulties with sleep patterns.
Increased sweating or hyperhidrosis.
Increased appetite leading to weight changes in some cases.
Bone mineral density reduction causing osteoporosis and increased fracture risk over long-term use.
Rare but serious cardiac events such as myocardial infarction or angina have been reported.
Potential for allergic reactions including rash or hypersensitivity.
Possible disturbances in liver function tests necessitating periodic monitoring.
Gastrointestinal discomfort including diarrhea or abdominal pain in some patients.
Changes in lipid profiles with possible elevations in cholesterol.
Mood alterations including anxiety or depression have been infrequently reported.

Precautions

Assess bone mineral density before and during treatment due to risk of osteoporosis and fractures.
Ensure adequate vitamin D and calcium intake or supplementation to mitigate bone loss.
Avoid use in premenopausal women and men due to lack of safety and efficacy data.
Pregnant or potentially pregnant women must not receive exemestane due to teratogenic risk.
Caution in patients with hepatic impairment; monitor liver function closely.
Evaluate cardiac risk factors prior to initiation due to associated increased risk of cardiac events.
Continuous contraception recommended in women who may become pregnant during treatment.
Patients should be monitored for symptoms of severe allergic reactions or hypersensitivity.
Advise patients to report unusual bone pain or signs of fractures promptly.
Dose modification may be considered when concomitant potent CYP3A4 inducers are administered.
Use caution when co-administering estrogen-containing medications, as these reduce exemestane efficacy.
Patients should be counseled about increased photosensitivity and sun exposure precautions.
Regular follow-up for clinical and laboratory assessments to detect adverse effects early.
Consider alternative therapies in patients with significant osteoporosis or fracture history.

Warnings

Risk of significant bone loss and osteoporosis associated with prolonged estrogen suppression.
Not indicated for use in premenopausal women or men; potential for serious adverse effects.
Teratogenicity: Use is contraindicated during pregnancy; effective contraception necessary.
Potential cardiac adverse events including heart attack and angina have been observed.
Exemestane may increase risk for severe allergic or hypersensitivity reactions.
Increased sensitivity to sunlight may lead to enhanced risk of sunburn and skin damage.
Discontinuation due to adverse effects is relatively uncommon but monitored for patient safety.
Hepatic impairment may increase systemic drug levels and adverse reactions.
Avoid concomitant use with estrogen-containing therapies to prevent loss of efficacy.
Patients should not abruptly discontinue therapy without medical advice due to cancer progression risk.
Drug interactions with CYP3A4 inducers may reduce therapeutic effects requiring dosing adjustments.
Close monitoring advised in elderly patients who may be more susceptible to adverse effects.
Clinicians should remain vigilant for signs of mood changes or depression during therapy.

Contraindication

Known hypersensitivity or allergy to exemestane or any of the inactive ingredients in the tablets.
Premenopausal women, as exemestane is ineffective and potentially harmful in this population.
Pregnancy due to established teratogenic effects and risk of fetal harm.
Breastfeeding women, as the drug's safety profile for infants is unknown and it may pass into milk.
Male patients, because exemestane has not been studied or approved for use in men.
Concurrent use with estrogen-containing medications that may negate exemestane's therapeutic effect.
Severe hepatic impairment without adequate risk-benefit evaluation.
Patients with osteoporosis without adequate management or monitoring due to high fracture risk.
Patients with uncontrolled cardiac disease or recent myocardial infarction should avoid use until stabilized.
Known severe allergic reactions to steroidal aromatase inhibitors or structurally related compounds.

Drug Interactions

Estrogen-containing therapies such as hormone replacement therapy or contraceptives reduce exemestane efficacy.
Potent CYP3A4 inducers (e.g., rifampicin, phenytoin) can increase exemestane metabolism, lowering plasma levels and requiring dose adjustment.
Concomitant administration with strong CYP3A4 inhibitors may increase exemestane plasma concentrations, potentially increasing toxicity risk.
No significant interactions reported with commonly used drugs like NSAIDs, antihypertensives, or anticoagulants but clinical vigilance encouraged.
Exemestane's metabolism and pharmacokinetics may be altered by agents affecting liver enzyme activity.
Caution with other hepatically metabolized drugs to avoid additive hepatic burden.
Interactions with drugs affecting bone metabolism (e.g., bisphosphonates) require monitoring for enhanced bone effects.
Limited data on interactions with herbal supplements; patients should be encouraged to disclose all supplement use.
Potential interactions with CYP3A4 substrates due to competitive metabolism are not clinically significant.
No known effect on cytochrome P450 enzymes beyond CYP3A4 impacting other drug pathways.
Avoid concomitant use with drugs known to prolong QT interval until further safety evidence is available.
Therapeutic drug monitoring not routinely required but advisable in complex polypharmacy situations.
Inform healthcare providers of exemestane therapy when starting new medications to evaluate potential interactions.

Preparations Of The Drug

Aromasin exemestane 25 mg tablets contain mannitol, crospovidone, polysorbate 80, hypromellose, colloidal silicon dioxide, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, simethicone, polyethylene glycol 6000, sucrose, magnesium carbonate, titanium dioxide, methylparaben, and polyvinyl alcohol as excipients.
Generic exemestane formulations vary by manufacturer, including Algoven, Inc., Breckenridge Pharmaceuticals, and Cipla USA, Inc., each with unique inactive ingredient profiles including combinations of copovidone, crospovidone, hypromellose, magnesium stearate, mannitol, polyethylene glycol, silicified microcrystalline cellulose, sodium starch glycolate, and titanium dioxide.
Tablets are film-coated to facilitate swallowing and protect the active ingredient.
Stored at controlled room temperatures between 20°C and 25°C (68°F to 77°F) to maintain stability.
Available exclusively in 25 mg strengths to meet recommended therapeutic dose.
Manufacturers ensure pharmaceutical quality control for purity, potency, and consistency of exemestane tablets.
Packaging typically includes child-resistant containers to ensure safety.
Excipients are chosen to optimize tablet disintegration, bioavailability, and patient acceptability.
No injectable or alternative dosage forms of exemestane are currently available on the market.
Patients are advised to inspect tablets for any visible changes before use and report any abnormalities to their pharmacist.
Generic formulations comply with regulatory approval standards equivalent to the branded Aromasin tablets.
Product labeling includes comprehensive details on dosage, storage, warnings, and patient instructions.
Manufacturing processes adhere to current Good Manufacturing Practices (cGMP) as regulated by health authorities.
Differences in excipients across brands may affect tolerability in rare cases of hypersensitivity.
Consultation with a healthcare professional is recommended when switching between branded and generic formulations.